MedPath

Study on Inhaled Fexlamose for Treating Moderate to Severe COPD in Adults

7 months ago1 min read

Main Inclusion Criteria

Each participant must meet all the following criteria to be enrolled in this study:
  • Age and Gender: Participant is male or female, aged 40 to 80 years.
  • Diagnosis: Participant has a verified diagnosis of cigarette smoking-related COPD with FEV1 >25% and <60% of predicted normal at Visit 1.
  • Spirometry Performance:
    • Acceptability: Participant can perform acceptable spirometry (meeting ATS/ERS acceptability criteria) at Visits 1 and 2.
    • Repeatability: Participant can perform technically acceptable spirometry meeting repeatability criteria for FEV1 during at least 1 of the prebronchodilator assessments at Visits 1 and 2.
  • Medication: Participant is on stable maintenance COPD medications with no dose adjustments for ≥4 weeks prior to Screening and during the Screening Period.
  • Exacerbations: Participant has had ≤2 COPD exacerbations requiring hospitalization in the past year.

Main Exclusion Criteria

Participants meeting any of the following criteria will be excluded from the study.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.